Goodwin advised Burro on the round. Burro closed its $24 million Series B co-led by Catalyst Investors and Translink Capital. Existing investors S2G Ventures, Toyota Ventures, F-Prime...
Burro’s $24 Million Series B Funding Round
Synopsys’ Acquisition of ANSYS
Cleary Gottlieb Steen & Hamilton is representing Synopsys, while Skadden and Goodwin Procter are representing ANSYS on the deal. Synopsys, Inc. (Synopsys) announced its acquisition of...
Stirling Square, TA and Macquarie Capital’s SEK10.1 Billion Cash Offer for Byggfakta
Goodwin advised a consortium comprising Stirling Square, TA Associates and Macquarie Capital in its recommended public offer to acquire all shares in Byggfakta Group Nordic HoldCo...
Paindrainer AB’s Partnership with Dr. Edward Rubin
Goodwin advised Paindrainer AB on its commercial partnership agreement with Dr. Edward Rubin. Paindrainer AB announced a commercial partnership agreement with Dr. Edward Rubin, Past President of...
Kymera Therapeutics’ $316.2 Million Common Stock Offering
Goodwin Procter advised Kymera Therapeutics, Inc. on the offering, and Wilmer Cutler Pickering Hale and Dorr advised the underwriters. Kymera Therapeutics, Inc. (Nasdaq: KYMR) (“Kymera”) announced its...
Novo Nordisk’s Research Collaborations with Omega Therapeutics and Cellarity
Goodwin advised Flagship Pioneering on the matter. Hogan Lovells acted for Omega Therapeutics, Inc. Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) and Cellarity Inc. announced that Novo Nordisk...
TPI Composites, Inc.’s Refinancing Transaction with Oaktree
Lazard acted as TPI’s financial advisor. Goodwin Procter LLP acted as TPI’s legal advisor and Sullivan & Cromwell LLP acted as Oaktree’s legal advisor. TPI Composites,...
EMZ Partners’ Investment in H&Z Group
Goodwin has advised the European private equity firm EMZ Partners on the financing of the acquisition of a significant stake in H&Z Unternehmensberatung. H&Z Management Consulting...
HI-Bio’s $95 Million Series B Financing Round
Goodwin advised Human Immunology Biosciences (HI-Bio) on the round. Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs),...
Concentra Biosciences’ $185 Million Acquisition of Theseus Pharmaceuticals
Goodwin advised Theseus Pharmaceuticals on the sale to Concentra Biosciences, assisted by Gibson, Dunn & Crutcher LLP. Leerink Partners acted as Theseus’ financial advisor. Theseus Pharmaceuticals,...
Bristol Myers Squibb’s $4.1 Billion Acquisition of RayzeBio
Covington advised Bristol Myers Squibb on the transaction, while Cooley and Wilson Sonsini Goodrich & Rosati advised RayzeBio Inc. Goodwin advised Centerview Partners in its role...
Orrstown Financial Services’ Merger with Codorus Valley Bancorp
Raymond James & Associates, Inc. acted as financial advisor to Orrstown and delivered a fairness opinion to the Board of Directors of Orrstown. Goodwin Procter LLP...